NET vs. DOCS, YOU, WIX, SST, CNIC, SRAD, GVP, ARBB, CYN, and SLP
Should you be buying Netcall stock or one of its competitors? The main competitors of Netcall include Dr. Martens (DOCS), YouGov (YOU), Wickes Group (WIX), Scottish Oriental Smaller Cos (SST), CentralNic Group (CNIC), Stelrad Group (SRAD), Gabelli Value Plus+ Trust (GVP), Arbuthnot Banking Group (ARBB), CQS Natural Resources Growth and Income (CYN), and Sylvania Platinum (SLP). These companies are all part of the "computer software" industry.
Netcall vs.
Dr. Martens (LON:DOCS) and Netcall (LON:NET) are both small-cap consumer cyclical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership, dividends and community ranking.
69.5% of Dr. Martens shares are held by institutional investors. Comparatively, 69.3% of Netcall shares are held by institutional investors. 4.4% of Dr. Martens shares are held by company insiders. Comparatively, 11.5% of Netcall shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Netcall has a net margin of 14.99% compared to Dr. Martens' net margin of 7.89%. Dr. Martens' return on equity of 18.91% beat Netcall's return on equity.
Netcall received 151 more outperform votes than Dr. Martens when rated by MarketBeat users. However, 91.67% of users gave Dr. Martens an outperform vote while only 58.06% of users gave Netcall an outperform vote.
Netcall has a consensus price target of GBX 130, suggesting a potential upside of 15.19%. Given Netcall's stronger consensus rating and higher possible upside, analysts plainly believe Netcall is more favorable than Dr. Martens.
Dr. Martens has higher revenue and earnings than Netcall. Dr. Martens is trading at a lower price-to-earnings ratio than Netcall, indicating that it is currently the more affordable of the two stocks.
Dr. Martens pays an annual dividend of GBX 3 per share and has a dividend yield of 4.5%. Netcall pays an annual dividend of GBX 1 per share and has a dividend yield of 0.9%. Dr. Martens pays out 42.5% of its earnings in the form of a dividend. Netcall pays out 28.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Dr. Martens has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Netcall has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.
In the previous week, Dr. Martens and Dr. Martens both had 1 articles in the media. Netcall's average media sentiment score of 0.67 beat Dr. Martens' score of 0.00 indicating that Netcall is being referred to more favorably in the news media.
Summary
Netcall beats Dr. Martens on 11 of the 19 factors compared between the two stocks.
Get Netcall News Delivered to You Automatically
Sign up to receive the latest news and ratings for NET and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (LON:NET) was last updated on 2/22/2025 by MarketBeat.com Staff
Free NET Stock Alerts